Pathstone Holdings’s Orchestra BioMed OBIO Stock Holding History

Pathstone Holdings’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,006,018	Closed	-$2.49M	–	2334
2025 Q3	$2.49M	Buy	+1,006,018	New	+$2.78M	0.01%	899

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

DMKJ

David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Pathstone Holdings's OBIO Position: Q4 2025 in Review

Pathstone Holdings sold out of Orchestra BioMed (OBIO) in Q4 2025, closing a stake of 1,006,018 shares — an estimated $2.49M sold.

Pathstone Holdings first reported a position in OBIO in Q3 2025 and held it in 1 quarter. The position peaked at $2.49M in Q3 2025. 63 funds tracked by Wall St. Rank hold OBIO as of Q4 2025.

Pathstone Holdings reported no remaining Orchestra BioMed position as of Q4 2025 after selling out during the quarter.
Pathstone Holdings sold 1,006,018 Orchestra BioMed shares in Q4 2025, an estimated $2.49M.
Pathstone Holdings first reported a position in Orchestra BioMed in Q3 2025 and held it in 1 quarter.
Pathstone Holdings's Orchestra BioMed position peaked at $2.49M in Q3 2025.
63 funds tracked by Wall St. Rank held Orchestra BioMed as of Q4 2025.

Based on Pathstone Holdings's 13F filing for Q4 2025, filed 13 Feb 2026.